← Leaderboards
Matthew J Bott
Sloan-Kettering Inst Can Research
$1,300,495
Attributed
$1,300,495
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $260.1K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,300,495 · 1
By mechanism
K08$1,300,495 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Scott W Lowe$63,222,126
- Corina Amor Vegas$4,067,163
- Richard John Bennett$14,709,057
- David B. Solit$21,393,031
- Edwin Charles Pratt$687,237
Others in their field
Other Emerging Leaders on “Cytotoxicity”
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
- John Damon Chodera · Sloan-Kettering Inst Can Research$15,076,495
- Wilton B Williams · Duke University$11,406,665
- Deanna A Kulpa · Emory University$10,394,989
- Elizabeth Fox · St. Jude Children'S Research Hospital$8,840,232
- Mara Becker · Duke University$6,798,777
Research focus
CytotoxicityDrug CombinationsConventional TherapyBasic ScienceCytokineAutologousAnti-Pd-L1AffectCareerCdk4 GeneCancer BiologyCell Cycle ArrestCell DeathCellsCancer EtiologyCheckpoint InhibitionChemotherapyCancer TherapyCisplatinCoculture TechniquesCombination Drug TherapyCombinatorialCell AgingDrug Discovery
Grant awards (5)
Exploring the combinatorial efficacy between chemotherapy and T cell checkpoint inhibition and the role of cellular senescence$260,099
K08 · FY2024 · CA · contact PI
Exploring the combinatorial efficacy between chemotherapy and T cell checkpoint inhibition and the role of cellular senescence$260,099
K08 · FY2023 · CA · contact PI
Exploring the combinatorial efficacy between chemotherapy and T cell checkpoint inhibition and the role of cellular senescence$260,099
K08 · FY2022 · CA · contact PI
Exploring the combinatorial efficacy between chemotherapy and T cell checkpoint inhibition and the role of cellular senescence$260,099
K08 · FY2021 · CA · contact PI
Exploring the combinatorial efficacy between chemotherapy and T cell checkpoint inhibition and the role of cellular senescence$260,099
K08 · FY2020 · CA · contact PI